C75D1ZZ
Nonimaging Nuclear Medicine Probe Lymphatics, Pelvic to None with None, Technetium 99m (Tc-99m) Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | C Nuclear Medicine |
| Body System | 7 Lymphatic and Hematologic System |
| Operation | 5 Nonimaging Nuclear Medicine Probe |
| Body Part | D Lymphatics, Pelvic |
| Approach | 1 Technetium 99m (Tc-99m) |
| Device | Z None |
| Qualifier | Z None |
Operation Definition
Introduction of radioactive materials into the body for the study of distribution and fate of certain substances by the detection of radioactive emissions; or, alternatively, measurement of absorption of radioactive emissions from an external source
Procedure Overview
This family covers nuclear medicine probe studies of the lymphatic and blood-forming systems, most often sentinel lymph node localization before breast cancer or melanoma surgery, and splenic or bone marrow uptake studies using an external radiation detector rather than a camera. A small dose of a radioactive tracer, such as technetium-99m sulfur colloid, is injected near a tumor or into a vein, and a handheld probe measures the emissions at the skin surface or during surgery to pinpoint the first lymph node likely to receive tumor drainage or to assess uptake in the spleen or marrow. No image is produced; the probe instead gives the surgeon or physician a numeric count or audible signal marking where activity concentrates. Sentinel node mapping lets a surgeon remove only the node most likely to harbor cancer cells rather than a full lymph node dissection, sparing patients the swelling and nerve injury that come with more extensive surgery, while marrow and splenic probe studies help characterize blood disorders or unexplained cytopenias.
Anatomy & Axis Detail
Lymphatics, Pelvic
Pelvic lymphatics include the external and internal iliac, obturator, and presacral nodal chains that receive drainage from the bladder, prostate, cervix, uterus, and rectum, making them a primary target for sentinel node identification in gynecologic and urologic oncology. A nonimaging probe is used intraoperatively after injection of a radiotracer near the primary tumor, allowing the surgeon to localize the first-echelon node draining that organ and limit lymphadenectomy to a focused, mapped area. This is particularly valuable in early-stage cervical and endometrial cancer and in prostate cancer staging, where extended pelvic dissection carries meaningful morbidity. Because pelvic sidewall anatomy places major vessels and the ureter near candidate nodes, probe guidance helps the surgeon confirm a true nodal target before excision rather than relying on visual inspection alone.
Radionuclide: Technetium 99m (Tc-99m)
Technetium 99m (Tc-99m) is the most widely used radionuclide in Nuclear Medicine, valued for its short half-life and favorable gamma energy for imaging bone, cardiac, renal, and other organ systems. In this axis position it records that a technetium-based radiopharmaceutical was the tracer administered for the study, distinguishing it from the many other specific isotopes, such as thallium or iodine compounds, used for more specialized indications.
Coding & Documentation
Coders assign from this family when the documentation confirms the study measured radioactive emissions with a probe, not a gamma camera producing a picture, so operative and nuclear medicine notes must be read carefully to distinguish probe-guided localization from planar or SPECT imaging of the same nodal basin. The radiotracer injection and the probe reading are frequently performed as a single combined service with the sentinel node biopsy itself, and the coder needs to separate the nuclear medicine component from the surgical excision reported elsewhere. A common error is coding this root operation when the physician actually obtained an image, which belongs under a different root operation, or omitting the code entirely because it was bundled conceptually with the surgery note rather than documented as its own service.